Pacific Biosciences of California, Inc. Aktie News

Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide NEW YORK and MENLO PARK, Calif. , June 2, 2025 /PRNewswire/ -- Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (Nasdaq: PACB), a leading provider of high-quality, highl...

MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the “Special Committee”) has concluded its independent investigation into previously disclosed allegations from an attorney representing an employee impacted by our recent reduction in force regarding certain employment practices and cybersecurity matt...

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance & Investor Relations Christian Henry - President & Chief Executive Officer Jim Gibson - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research David Westenberg - Piper Sandler William Ruby - TD C...

MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025.

Collaboration leverages HiFi's unique ability to reveal hidden variants, bringing a new level of precision to early life genetic screening Collaboration leverages HiFi's unique ability to reveal hidden variants, bringing a new level of precision to early life genetic screening

Company licenses novel deep learning-based epigenetic models from CUHK enabling the detection of 5hmC, 5mC hemimethylation, and 6mA in standard sequencing runs Company licenses novel deep learning-based epigenetic models from CUHK enabling the detection of 5hmC, 5mC hemimethylation, and 6mA in standard sequencing runs

International research team aims to develop better understanding of Alzheimer's disease and dementia in diverse populations International research team aims to develop better understanding of Alzheimer's disease and dementia in diverse populations

Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025.